Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussion highlights the importance of the study in advancing understanding of glucose control and vascular outcomes, with posts discussing related trials like ADVANCE and emphasizing the microvascular benefits, as well as concerns about hypoglycemia. The tone combines technical references and recognition of ongoing debates, reflecting a high interest and engagement in the subject's clinical relevance.
Most posts acknowledge the significance of the study, with some expressions supporting its findings on microvascular benefits.
Discussions demonstrate a high level of interest, referencing related trials, study details, and implications for treatment, indicating engagement with the topic.
Posts include references to additional studies, critique, and commentary, showing a moderate depth of engagement with the research methodology and clinical relevance.
The discussions emphasize the study’s implications for clinical practice and future research, but some posts focus more on background information and less on transformative impact.
Basically just bragging about how incredible our @UChiPritzker students are. These are the papers presented in our Critical Appraisal of the Landmark Medical Literature course today. I should be getting CME! https://t.co/YTYYx68y1F https://t.co/KPEnSlNRiH https://t.co/ZeRhgnNUvi
Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
As for ADVANCE, the first "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation" out in 2008, randomized diabetic patients to receive intervensive vs. standard control and looking at vascular outcomes. 4/ https://t.co/sMPCTRPBK0
@UweJhn1 References: 1/n Glucose control and vascular complications in veterans with type 2 diabetes - PubMed (https://t.co/Bsjhdq80tA) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes - PubMed (https://t.co/Bsjhdq80tA)
@UweJhn1 2/n https://t.co/uFjLI3wWqk https://t.co/J0wvyLfwfy https://t.co/XXk45orwPU https://t.co/g7uMpWmgaH
@kalashnikity @thelowcarb_rd Insulin resistance isn't the target for therapy with therapies that increase serum insulin; blood glucose is. This improves hyperglycemia-related outcomes. https://t.co/TTIG3u26xG
Intensive glucose control in patients with type 2 diabetes reduces microvascular complications like nephropathy but does not significantly improve macrovascular events or mortality, and increases hypoglycemia risk…
Prof Jörg Bojunga explains the optimal medication strategies for Type 2 Diabetes based on the National Guideline, discussing various drug classes and recent studies on insulin and cardiovascular outcomes.
There are 2 big lies about Type 2 Diabetes. It is often seen as a progressive, incurable disease, but in reality, it is primarily a lifestyle and nutritional disorder that can be reversed through dietary changes…
The study ACCORD explores the benefits and risks of intensive glucose control in type 2 diabetes, highlighting its impact on microvascular complications, macrovascular outcomes, and hypoglycemia risk over five years.
This video discusses a study on lixisenatide, a medication for type 2 diabetes, examining its effects on cardiovascular outcomes in patients with recent heart attacks or unstable angina. The medication was found to be…
@UweJhn1 2/n https://t.co/uFjLI3wWqk https://t.co/J0wvyLfwfy https://t.co/XXk45orwPU https://t.co/g7uMpWmgaH
@UweJhn1 References: 1/n Glucose control and vascular complications in veterans with type 2 diabetes - PubMed (https://t.co/Bsjhdq80tA) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes - PubMed (https://t.co/Bsjhdq80tA)
@kalashnikity @thelowcarb_rd Insulin resistance isn't the target for therapy with therapies that increase serum insulin; blood glucose is. This improves hyperglycemia-related outcomes. https://t.co/TTIG3u26xG
RT @redGDPS: Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type2 Diabetes Read more at: https://t.co/nTCP5pd2eL @macmahonstephen @BruceNeal1 @LaurentJBillot @PaulGlasziou @Grobbee @simonrheller @rohinajoshi @Sydney_Uni @IcahnMountSinai @HRIAust @UQ_News @UniofOxford https://t.co/RV1Wojtu15
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type2 Diabetes Read more at: https://t.co/nTCP5pd2eL @macmahonstephen @BruceNeal1 @LaurentJBillot @PaulGlasziou @Grobbee @simonrheller @rohinajoshi @Sydney_Uni @IcahnMountSinai @HRIAust @UQ_News @UniofOxford https://t.co/RV1Wojtu15
Basically just bragging about how incredible our @UChiPritzker students are. These are the papers presented in our Critical Appraisal of the Landmark Medical Literature course today. I should be getting CME! https://t.co/YTYYx68y1F https://t.co/KPEnSlNRiH https://t.co/ZeRhgnNUvi
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes | NEJM https://t.co/LxfQxTbJqG
As for ADVANCE, the first "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation" out in 2008, randomized diabetic patients to receive intervensive vs. standard control and looking at vascular outcomes. 4/ https://t.co/sMPCTRPBK0
RT @redGDPS: Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
RT @redGDPS: Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
RT @redGDPS: Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
Mitos y leyendas de las #sulfonilureas https://t.co/ZMF3DSrukR #3RSredgdps https://t.co/FSAfGwKaJJ
(1/2)Trial of the day: ADVANCE Patel A, et al. "Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes". The New England Journal of Medicine. 2008. 358(24):2560-2572. https://t.co/ujL2ndwA6d #FOAMcards
S